Antibody-mediated lymphocyte depletion is frequently used as induction therapy in sensitized transplant patients. Although T cells with an effector/memory phenotype remain detectable after lymphoablative therapies in human transplant recipients, the role of preexisting donor-reactive memory in reconstitution of the T cell repertoire and induction of alloimmune responses following lymphoablation is poorly understood. We show in a mouse cardiac transplantation model that antidonor immune responses following treatment with rabbit antimouse thymocyte globulin (mATG) were dominated by T cells derived from the preexisting memory compartment. Administration of mATG 1 week prior to transplantation (pre-TP) was more efficient in targeting preexisting donor-reactive memory T cells, inhibiting overall antidonor T cell responses, and prolonging heart allograft survival than the commonly used treatment at the time of transplantation (peri-TP). The failure of peri-TP mATG to control antidonor memory responses was due to faster recovery of preexisting memory T cells rather than their inefficient depletion. This rapid recovery did not depend on T cell specificity for donor alloantigens suggesting an important role for posttransplant inflammation in this process. Our findings provide insights into the components of the alloimmune response remaining after lymphoablation and may help guide the future use of ATG in sensitized transplant recipients.
The presence of donor-reactive memory T cells prior to transplantation results in robust immune responses to transplanted organs leading to poor graft outcome in humans and accelerated allograft rejection in animal models [1-5]. Activated donor-specific memory T cell subsets mediate allograft injury through a variety of mechanisms. We have previously reported that memory CD4 T cells provide efficient help for activation of naive donor-reactive CD4 and CD8 T cells and alloantibody production that in turn mediate allograft destruction [6-8]. In addition, the initial contact of endogenous memory CD8 T cells with the donor endothelium early posttransplant promotes the infiltration of recipient leukocytes into the graft via activation of endothelial cells and upregulation of adhesion molecules and chemokines [9, 10].
Lymphoablative agents such as polyclonal antithymocyte globulin (ATG) or monoclonal anti-CD52 antibody are commonly used as induction therapy in transplantation, particularly in highly sensitized patients and in patients receiving deceased donor and other marginal grafts [11-14]. A problem with the use of these agents is that memory T cells are less susceptible to depletion strategies [15-18]. Studies in nonhuman primates and human transplant recipients demonstrate that T cells with an effector/memory phenotype are detectable after anti-CD52 mAb or ATG induction and are associated with acute rejection episodes [19, 20]. These activated T cells could arise from preexisting memory T cells resistant to depletion therapy or from residual naive T cells in response to the allograft and during homeostatic proliferation in the lymphopenic host. However, the origin of these cells, as well as their numbers, anatomical distribution, and effects on graft survival cannot be rigorously tested in human patients.
A rabbit antimouse thymocyte globulin (mATG), comparable with the commercial product used in clinical transplantation, was recently generated . Similar to the use of other depletion strategies, memory T cells are not entirely depleted in naive nontransplanted mice even by high doses of the mATG [21, 22]. A recent study of nontransplanted mice treated with mATG suggested that memory T cells do not have an advantage in proliferation over naive T cells in ATG-generated lymphopenic conditions . However, the susceptibility of distinct donor-reactive memory T cell subsets to mATG depletion and the potential homeostatic or antigen-driven proliferation of the remaining memory T cells in the presence of an allograft have not been previously determined. The goals of our current study were to address these questions in a murine model of cardiac transplantation and to test whether the pathogenic functions of preexisting alloreactive memory T cells can be diminished by altering the timing of mATG administration.
Our results show that antidonor immune responses after mATG depletion were dominated by T cells derived from the preexisting memory compartment. Strikingly, administration of mATG 1 week prior to transplantation (pre-TP) was substantially more efficient in targeting preexisting donor-reactive memory T cells, inhibiting overall antidonor T cell responses, and prolonging heart allograft survival than the commonly used mATG treatment at the time of transplantation (peri-TP). The inferior ability of peri-TP mATG to control antidonor memory responses was due to faster recovery of preexisting memory T cells rather than their inefficient depletion. This rapid recovery did not depend on T cell specificity for donor alloantigens suggesting an important role for posttransplant inflammation in this process.
Materials and Methods
The following mice, aged 6–8 weeks, were purchased from the Jackson Laboratories (Bar Harbor, ME): male C57BlL/6J (H-2b) [B6], congenic male B6.PL-Thy1a/Cy (H2b) [Thy1.1] and female B6.SJL-Ptprca Pep3b/ByJ [CD45.1], male BALB/cJ (H-2d) [BALB/c], female C3H/HeJ MMTV (H2k) [C3H] and female SJL/J-Pde6brd1 (H2s) [SJL]. 2C TCR transgenic mice on B6 background (H2b) were provided by Dr. Robert Fairchild (Cleveland Clinic). All animals were maintained and bred in the pathogen-free facility at the Cleveland Clinic. All procedures involving animals were approved by the Institutional Animal Care and Use Committee at the Cleveland Clinic.
Heart transplantation and recipient treatment
Vascularized heterotopic cardiac allografts were placed in the abdomen of recipient mice using standard techniques and monitored as previously described [6, 7, 23]. Rejection was defined as the absence of a palpable heart beat and confirmed by laparotomy. Grafts were recovered at the time of rejection or at indicated time points, embedded in paraffin and stained with H&E and anti-C4d antibody as previously published . Rabbit antimouse thymocyte globulin (mATG) and control rabbit IgG were generated by Genzyme as previously described . Heart allograft recipients were treated with mATG or control rabbit IgG (0.5 mg/injection in BALB/c recipients and 0.5 mg or 1mg/injection in B6 recipients) either on days −7 and −4 (pre-TP mATG) or on days 0 and 4 (peri-TP mATG) relative to the transplantation.
Flow cytometry phycoerythrin (PE)-conjugated antimouse CD4, fluorescein isothiocyanate (FITC)-conjugated antimouse CD4, allophycocyanin (APC)-conjugated antimouse CD8, PE-conjugated antimouse anti-CD44, peridinin-chlorophyll protein (PerCP)-conjugated antimouse CD44, FITC-conjugated antimouse CD45.1, APC-conjugated antimouse CD45.1, FITC-conjugated antimouse CD45.2, PE-conjugated antimouse Thy1.1, FITC-conjugated antimouse Thy1.2, PE-conjugated antimouse CD62L were purchased from BD Pharmingen (San Diego, CA, USA) or from eBioscience (San Diego, CA, USA). Cells were isolated from peripheral blood, spleen, bone marrow, lung and liver and stained with indicated reagents as previously described [6, 7, 23]. For intracellular staining, cells initially stained for cell surface markers were fixed with 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA, USA), washed and incubated for 1 hour at room temperature with PE-conjugated antimouse Ki-67 antibody (eBioscience) in PBS plus 0.1% bovine serum albumin and 0.1% saponin. The labeled cells were washed in PBS plus 0.1% BSA and 0.02% NaN3 and resuspended in PBS. At least 200 000 events/sample were acquired on a BD Bioscience FACSCalibur (BD Biosciences, San Diego, CA) followed by data analysis using FlowJo software (Tree Star Inc., Ashland, OR, USA).
Adoptive transfer experiments
To generate alloreactive memory T cells, BALB/c skin allograft were placed onto B6 or 2C TCR transgenic recipients. Four weeks after transplantation, total T cells were isolated from recipient spleens by negative selection using commercially available murine T cell isolation columns from R&D Systems (Minneapolis, MN) or EasySep magnetic bead particles from STEMCELL Technologies (Vancouver, BC). After T cell enrichment, cells were resuspended at 10 × 106/mL in PBS+ 2% Fetal Bovine Serum, and labeled using antibodies against CD4, CD8 and CD44 for 30 min on ice followed by two washes. CD4+CD44hi T cells and CD8+CD44hi T cells were then sorted on a FACSAria II sorter (BD Biosciences). Analogously, CD4+CD44lo and CD8+CD44lo T cells were sorted from spleens of naive congenic B6 mice. Then, 2 × 106 sorted naive or memory CD4 and CD8 T cells were intravenously injected into congenic Thy1 or CD45 disparate B6 mice (see Figure 4A for detailed experimental design). In some experiments, isolated memory T cells were labeled with carboxyfluorescein diacetate, succinimidyl ester (CFSE) as previously published . Briefly, cells were resuspended at 20 × 106/mL in PBS and incubated with 1.25μM CFSE for 8 min at room temperature. The staining was stopped by the addition of equal volume of fetal calf serum (FCS, Atlanta Biologicals, Lawrenceville, GA, USA) followed by 1 min incubation. Stained cells were washed twice with RPMI1640 (Gibco Life Technologies, Grand Island, NY, USA) plus 10% FCS, counted and used for adoptive transfer experiments.
Assays were performed as previously described using capture and detecting antimouse IFNγ antibody from BD Pharmingen . Recipient spleen cells were stimulated with mitomycin C-treated BALB/c, SJL or B6 spleen cells for 24 h. Responder cells were titrated from 400 000 to 20 000 per well with the addition of 400 000 stimulator cells per well. The resulting spots were analyzed using an ImmunoSpot Series 4 analyzer (Cellular Technology, Cleveland, OH, USA).
Heart allograft survival was compared between groups by Kaplan–Meier analysis. All other results were analyzed by a nonparametric Mann–Whitney test. Total numbers of animals per experimental groups are indicated in figure captions. A p value < 0.05 was considered a significant difference. Unless noted otherwise, the data were represented as mean values ± SD.
T cells with an effector/memory phenotype are more resistant to mATG-mediated depletion than naive T cells
Naive 4- to 6-week-old B6 mice contain endogenous effector/memory CD44hi CD4 and CD8 T cells (3–5% of total splenocytes). Some of these cells are reactive to alloantigens and secrete the effector cytokine IFNγ in short-term ELISPOT assays [28, 29]. In initial experiments, we evaluated the effects of mATG on endogenous memory T lymphocyte subsets in naive nontransplanted B6 mice. Consistent with previous reports [21, 22], two injections of mATG (25mg/kg) depleted 95–98% of T cells in the circulation and up to 95% T cells in the spleen with more prominent effects on CD8 than on CD4 T cells (Figures S1 and 1A). The residual CD4 and CD8 T lymphocytes were enriched for cells with a CD44hi effector/memory phenotype (Figures S1 and 1B). IFNγ ELISPOT assays performed prior to and following depletion showed that mATG treatment significantly decreased the frequencies as well as the total numbers of alloreactive T cells (Figure 1C and not shown). Nevertheless, alloreactive memory T cells still remained detectable in the spleens of mATG-treated mice with a potential to undergo activation by donor antigens and contribute to allograft rejection after transplantation (Figure 1C).
Pretransplant administration of mATG is more efficient in prolonging heart allograft survival and inhibiting antidonor T cell responses than treatment at the time of transplantation
We next tested whether administration of mATG prior to reactivation with alloantigen will be more efficient in depleting donor-reactive memory T cells and in prolonging heart allograft survival than peri-transplant treatment. BALB/c (H-2d) recipients of B6 (H-2b) heart allografts and B6 recipients of BALB/c heart allografts were treated with mATG either on days −7 and −4 before transplantation (pre-TP) or on days 0 and 4 after transplantation (peri-TP). Two pre- or peri-TP injections of 0.5 mg mATG prolonged cardiac allograft survival in BALB/c recipients compared to control IgG-treated mice (Figure 2A). However, the same mATG treatments had more modest effects in B6 recipients of BALB/c heart allografts (MST of 6.0 ± 0.6, 8.0 ± 0.6 and 11.5 ± 0.3 days for control IgG, peri-TP and pre-TP treatments, respectively) consistent with previous data on the resistance of the B6 strain to graft-prolonging therapies [30, 31]. Increasing the dose of mATG to 1 mg/injection resulted in improved graft survival in B6 recipients (Figure 2B). The differences in allograft survival time between mATG-treated B6 and BALB/c recipients was likely to result from higher immunogenicity of BALB/c heart allografts rather than from different numbers of preexisting memory T cells or to the different T cell susceptibility to mATG depletion between two strains (Figure S2). Importantly, regardless of the donor/recipient strain combination or mATG dose, pre-TP mATG resulted in better allograft outcome than peri-TP treatment.
In both mATG-treated groups, the rejecting heart allografts were heavily infiltrated with mononuclear cells characteristic of acute cellular rejection. In addition, immunohistochemical staining revealed diffuse deposition of the complement split product C4d on graft capillaries (Figure 2C). Consistent with these findings, comparable titers of donor-reactive IgG alloantibodies were detected in serum of recipients treated with mATG pre- or peri-TP at the time of rejection (data not shown). Thus, neither pre- nor peri-TP mATG treatment entirely eliminates CD4 T cell help for alloantibody production and the grafts rejected by mATG-treated recipients demonstrate signs of antibody-mediated injury.
We next tested whether prolonged heart allograft survival in the pre-TP mATG-treated group was associated with more efficient depletion of recipient T lymphocytes. Both mATG treatment regimens resulted in prominent depletion of CD44lo as well as CD44hi T cells compared to rIgG treatment. At the time of rejection, recipients treated with mATG either pre- or peri-TP had comparable percentages and numbers of total CD4 and CD8 T cells and CD44hi CD4 and CD8 T cells in the spleen (Figure 3A) and in the peripheral blood (not shown). Despite the massive T cell depletion by peri-TP mATG, however, the frequencies of spleen cells secreting IFNγ in response to donor antigens were similar to those in nondepleted mice (Figure 3B). Furthermore, the residual CD44hi population was enriched for donor-reactive IFNγ-producing T cells compared to nondepleted recipients (Figure 3C). In contrast, pre-TP administration of mATG resulted in significantly lower frequencies of donor-specific IFNγ-secreting T cells compared to peri-TP mATG and to the control rIgG treatment and did not lead to the accumulation of donor-reactive T cells with an effector/memory phenotype.
Pre-TP mATG results in greater inhibition of preexisting donor-reactive memory T cell responses than peri-TP treatment
To dissect the effects of mATG treatment on preexisting memory versus naive T cells, we generated B6 mice containing congenic populations of naive CD4 and CD8 and BALB/c-reactive memory CD4 and CD8 T cells so as to track each subset separately within the same recipient (Figure 4A). These recipients were transplanted with BALB/c heart allografts and treated with mATG or with control rabbit IgG either pre- or peri-TP. The numbers of transferred cells in spleen and peripheral blood were determined by flow cytometry on day 10 after transplantation. Recall IFNγ production by recipient spleen cells was comparable to that in the absence of T cell transfer (Figures 4B–C) indicating that injected tracer T cell subsets did not significantly alter overall antidonor responses. Whereas both mATG regimens resulted in prominent reduction in numbers of T cells derived from naive precursors, pre-TP mATG was significantly more efficient than peri-TP treatment in decreasing numbers of CD4 and CD8 T cells derived from preexisting memory populations (Figure 4C–D, Figure S3). Furthermore, pre-TP mATG inhibited donor–specific IFNγ production by residual memory T cells to a greater degree than peri-TP administration (Figure 4E). Similar reduction in tracer memory T cell numbers in pre- versus peri-TP mATG-treated recipients was observed on day 7 after transplantation (20 645 ± 12 466 vs. 187 573 ± 82 229 transferred memory T cells per spleen, respectively).
Unequal precursor frequencies of polyclonal alloreactive T cells within naive and memory populations could potentially influence the accumulation of these cells in mATG-treated allograft recipients. To rule out this possibility, we performed analogous experiments using 2C TCR transgenic CD8 T cells reactive to Ld class I MHC molecule expressed by H-2d BALB/c mice. The results were similar to those observed with polyclonal CD4 and CD8 T cells confirming the superior control of preexisting memory T cells by pre-TP mATG (Figure 4F).
In contrast to pre-TP mATG, peri-TP lymphoablation results in faster recovery of preexisting memory T cells regardless of their antigen specificity
In our adoptive transfer experiments, both the efficiency of memory T cell depletion and their homeostatic and antigen-driven expansion can contribute to cell numbers observed on day 10 after transplantation. We next tested whether the presence of specific antigens and rapid reactivation of memory T cells undermines their depletion by peri-TP mATG. Groups of B6 recipients containing tracer subsets of donor-reactive memory T cells received a single injection of 1 mg mATG pre- or peri-TP and were killed 2 days later (prior to graft placement in the pre-TP-treated group and on day 2 posttransplant in the peri-TP-treated group) to eliminate the contribution of T cell expansion. Unexpectedly, the numbers of residual memory T cells were similar in both groups regardless of the presence of an allograft (Figure 5). These findings suggested that accelerated expansion rather than inefficient depletion of donor-specific memory T cells accounts for their increased accumulation in peri-TP-treated recipients. To examine this possibility, donor-reactive memory T cells were labeled with CFSE prior to the adoptive transfer into heart allograft recipients treated with mATG or control rIgG. The proliferation history and ongoing cell division were assessed at day 7 posttransplant by CFSE dilution and intracellular staining for nuclear protein Ki-67, respectively. Both approaches showed that the proliferation of tracer memory T cells was increased in recipients treated with mATG peri-TP compared to the pre-TP-treated group (Figure 6). Notably, memory T cell in pre-TP-treated recipients mostly expanded prior to transplantation and did not proliferate further after allograft placement (day −1 vs. day 7 time point in Figure 6).
We next tested whether memory T cells specific for donor alloantigens preferentially expand and accumulate in lymphopenic host after peri-TP mATG treatment. B6 recipients injected with congenic 2C memory T cells were transplanted with either Ld+ BALB/c or Ld− SJL heart allografts or with B6 heart isografts and treated with mATG or control rabbit IgG at the time of transplantation. As anticipated, reactivation with Ld alloantigen led to increased numbers of transferred 2C cells in control-treated recipients compared to the control SJL allograft or B6 isograft recipients (Figure 7A). In allograft recipients, peri-mATG was equally potent in reducing the numbers of 2C cells in comparison to control-treated mice regardless of donor Ld expression (Figure 7B). Thus, the faster recovery of memory T cells observed after peri-TP mATG administration does not depend on their specificity for donor alloantigens. The recovery of 2C cells in isograft recipients was compromised compared to both types of allograft recipients.
Lymphoablation is commonly used as an induction therapy in transplant patients [11-14]. Previous studies in nonhuman primates and in human transplant patients demonstrated that T cells with an activated/memory phenotype are detectable in the circulation after lymphoablative therapies and are associated with the recovery of antidonor cellular reactivity and acute rejection episodes [15, 20, 26]. In theory, these cells can arise from preexisting memory T cells resistant to depletion therapy, from residual naive T cells in response to the allograft and during homeostatic proliferation in the lymphopenic host or from naive T cells newly generated in the thymus. This is highly relevant to clinical practice as one indication for the use of T cell depleting agents is the recipient's previous sensitization to donor or third party alloantigens. However, the effects of depletion therapies on different arms of the memory immune response have not been previously assessed. In this study, we evaluated whether ATG treatment controls preexisting donor-reactive memory T cells and investigated the origin of antidonor alloreactivity in ATG-treated murine heart allograft recipients. We realize that the polyclonal anitbodies raised against rodent cells may have different spectra of specificities and biological effects from antihuman thymoglobulin. One well-documented example of such differences is the depletion of B lymphocytes by antihuman thymoglobulin but not by mATG [14, 21]. Nevertheless, both antihuman and antimurine ATG have high potency in depleting T lymphocytes thus justifying the use of mATG in mouse model of transplantation to study T cell depletion and recovery following ATG induction.
Consistent with previous studies using various depletion agents, T cells remaining in the periphery of nontransplanted mice after mATG treatment were enriched for the effector/memory phenotype [16, 17, 21, 22, 32, 33]. Despite prominent T lymphocyte depletion in the peripheral blood and spleen, memory T cells within the bone marrow and nonlymphoid tissues such as lung and liver were more resistant to the effects of mATG (data not shown). Ongoing studies in our laboratory will investigate whether this resistance is due to anatomical location and inaccessibility to circulating mATG or due to intrinsic properties of memory T cells from specific tissue compartments. Furthermore, the contributions of residual T cells from different compartments to host T cell repertoire reconstitution and to subsequent responses against transplanted organ remain to be determined.
In the absence of other immunosuppression, peri-TP mATG treatment resulted in modest prolongation of cardiac allograft survival in two different recipient strains. Despite initial depletion of both naive and memory T cells, antidonor responses in recipients treated with peri-TP mATG were either comparable to or exceeded those in control nondepleted recipients on day 10 posttransplant and at the time of rejection (Figures 3B-C and Figure 4B). Using the adoptive transfer system that allowed simultaneous tracing of both naive and memory T cell populations within the same recipient, we demonstrated for the first time that preexisting donor-reactive memory T cells contribute significantly to the antidonor immune responses observed in mATG-treated heart allograft recipients. The presence of an allograft may play an important role in the recovery of different T cell subsets as Sener and colleagues previously reported that memory T cells do not have an advantage in proliferation over naive T cells in ATG-treated nontransplanted mice .
We reasoned that memory T cell depletion in the absence of donor antigens and inflammation inflicted by the surgery may be more prominent and thereby beneficial for graft outcome and tested this by administering mATG prior to transplantation (pre-TP). Pre-TP mATG was much more efficient than peri-TP treatment in inhibiting overall antidonor T cell responses, reducing the numbers of preexisting CD4 and CD8 donor-reactive memory T cells and prolonging heart allograft survival (Figures 2-4, Figure S3). Unexpectedly, the presence of an allograft at the time of mATG administration did not result in inferior depletion of memory or naive T cells (Figure 5). Instead, the higher numbers of donor-reactive T cells derived from memory precursors were likely to be due to the more efficient expansion of memory T cells in peri-TP-treated recipients (Figure 6). The superior homeostatic proliferation of memory over naive T cells after lymphoablation in naive mice has been reported ; however, the influence of an allograft on this process has not been previously assessed. While donor alloantigens played a role in the overall accumulation of donor-reactive memory T cells, nonspecific memory T cells transferred into heart allograft recipients demonstrated similar rates of recovery suggesting that posttransplant inflammation at the time of depletion enhances their homeostatic expansion. Conversely, the recovery of donor-reactive memory T cells may be impeded by currently used immunosuppression as suggested by the kinetics of T cell repopulation in human transplant patients after lymphodepletion [20, 26]. Notably, the recovery of memory T cells in isograft recipients was compromised compared to the recipients of both specific antigen expressing and nonexpressing allografts (Figure 7). These findings are consistent with previously reported lower levels of early and late posttransplant inflammation in iso- versus allografts [10, 34, 35]. Our laboratory is currently investigating how transplantation-induced inflammatory cytokines such as TNFα and IL-1 and the timing of the exposure to these factors affect homeostatic and antigen-driven expansion of memory T cells.
The contribution of depletion-resistant memory T cell subsets and their descendants to graft rejection may vary at different stages after transplantation. For example, circulating donor-reactive memory CD8 T cells infiltrate the vascularized cardiac allograft within hours after transplantation and amplify early intragraft inflammation and subsequent recruitment of newly generated effector T cells [9, 10]. This mechanisms is operational in peri-TP mATG-treated recipients as the greatest level of T cell depletion is not achieved until 4–5 days after the mATG injection ((21) and data not shown). In contrast, preemptive lymphoablation significantly reduces the numbers of circulating T cells prior to transplantation thus alleviating early intragraft inflammation.
Our results strongly suggest that even in nonsensitized mice, endogenous memory T cells are a prominent component of antidonor immune responses after peri-TP lymphoablation and that targeting these memory T cells with pre-TP mATG administration significantly improves allograft outcome. In addition to effects on preexisting memory T cells, peri-TP mATG can trigger several other mechanisms of graft prolongation compared to pre-TP treatment. In addition to T cell depletion, mATG is likely to affect other types of recipient cells [14, 36-39]. For example, mATG injected at the time of transplantation can directly react with graft endothelial cells and augment their activation, cytokine and chemokine release as well as early complement deposition in the graft. This possibility is corroborated by clinical reports that horse ATG therapy was associated with the deposition of horse IgG and activation of complement in renal transplants and, in a few cases, induction with ATG led to hyperacute antibody-mediated rejection [34, 35]. In contrast, administration of mATG several days prior to the surgery is likely to result in significantly diminished binding of the rabbit antibody directly to the graft, as >95% of mATG is absorbed or cleared within 24 h after injection . We are currently evaluating the contribution of early ATG deposition in the graft to overall intragraft inflammation including cytokine and chemokine influx, donor alloantigens release and presentation and subsequent T cell recruitment.
Another possible factor modulating the efficacy of different mATG regimens is the kinetics of recipient and donor antigen presenting cell (APC) depletion. While pre-TP mATG reduced the number of peripheral CD11c+ cells (data not shown), depletion at the time of transplantation may allow both donor and recipient dendritic cells to present donor antigens prior to depletion by mATG. This early antigen presentation by professional antigen presenting cells may be especially important in enhancing the proliferation of antigen-experienced memory T cell subsets.
Among several proposed mechanisms of graft prolongation by ATG in human patients as well as in animal models is the expansion and function of T regulatory cells [32, 40, 41]. The absolute numbers of Foxp3+ T cells in the recipient spleen and heart allograft in our study were similar in all experimental groups arguing against the possibility that pre-TP mATG results in superior expansion of Tregs compared to peri-TP mATG administration. However, due to more prominent inhibition of memory T cell recovery and antidonor effector cell generation by pre-TP mATG, the decreased Teff/Treg ratio may influence allograft outcome in these recipients.
In summary, our results in a mouse cardiac allograft model strongly suggest that memory T cells can be a prominent component of ensuing antidonor immune responses in recipients undergoing lymphoablative therapy at the time of transplantation. Most remarkably, the graft-prolonging effects of ATG therapy and its ability to target preexisting memory T cells can be significantly increased by a pretransplant administration regimen. These findings provide insights into the components of the alloimmune response after lymphoablation and may guide the future use of ATG in sensitized transplant recipients.
We thank Nina Volokh and Earla Biekert for expert technical assistance. This work was supported by a 1P01 AI087586 grant and by a R01 AI058088 from the NIH (AV).
Rabbit antimouse thymocyte globulin (mATG) and control rabbit IgG were provided by Genzyme. The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.